Everything below concerns peptide hormone. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-01-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
In humans the main gluconeogenic precursors are lactate, glycerol (which is a part of the triglyceride molecule), alanine and glutamine. Altogether, they account for over 90% of the overall gluconeogenesis. Other glucogenic amino acids and all citric acid cycle intermediates (through conversion to oxaloacetate) can also function as substrates for gluconeogenesis. Generally, human consumption of gluconeogenic substrates in food does not result in increased gluconeogenesis. In ruminants, propionate is the principal gluconeogenic substrate. In nonruminants, including human beings, propionate arises from the β-oxidation of odd-chain and branched-chain fatty acids, and is a (relatively minor) substrate for gluconeogenesis. Lactate is transported back to the liver where it is converted into pyruvate by the Cori cycle using the enzyme lactate dehydrogenase. Pyruvate, the first designated substrate of the gluconeogenic pathway, can then be used to generate glucose. Transamination or deamination of amino acids facilitates entering of their carbon skeleton into the cycle directly (as pyruvate or oxaloacetate), or indirectly via the citric acid cycle. The contribution of Cori cycle lactate to overall glucose production increases with fasting duration. Specifically, after 12, 20, and 40 hours of fasting by human volunteers, the contribution of Cori cycle lactate to gluconeogenesis was 41%, 71%, and 92%, respectively. Whether even-chain fatty acids can be converted into glucose in animals has been a longstanding question in biochemistry.
Another important application of solvent extraction is in the separation of the lanthanoids. This process also uses TBP and the complexes are extracted into kerosene. Separation is achieved because the stability constant for the formation of the TBP complex increases as the size of the lanthanoid ion decreases. An instance of ion-pair extraction is in the use of a ligand to enable oxidation by potassium permanganate, KMnO4, in an organic solvent. KMnO4 is not soluble in organic solvents. When a ligand, such as a crown ether is added to an aqueous solution of KMnO4, it forms a hydrophobic complex with the potassium cation which allows the uncharged ion pair [KL]+[MnO4]− to be extracted into the organic solvent. See also: phase-transfer catalysis. More complex partitioning problems (i.e. 3 or more phases present) can sometimes be handled with a fugacity capacity approach.
Carbon dioxide was the first gas to be described as a discrete substance. In about 1640, the Flemish chemist Jan Baptist van Helmont observed that when he burned charcoal in a closed vessel, the mass of the resulting ash was much less than that of the original charcoal. His interpretation was that the rest of the charcoal had been transmuted into an invisible substance he termed a "gas" (from Greek "chaos") or "wild spirit" (spiritus sylvestris). The properties of carbon dioxide were further studied in the 1750s by the Scottish physician Joseph Black. He found that limestone (calcium carbonate) could be heated or treated with acids to yield a gas he called "fixed air". He observed that the fixed air was denser than air and supported neither flame nor animal life. Black also found that when bubbled through limewater (a saturated aqueous solution of calcium hydroxide), it would precipitate calcium carbonate. He used this phenomenon to illustrate that carbon dioxide is produced by animal respiration and microbial fermentation. In 1772, English chemist Joseph Priestley published a paper entitled Impregnating Water with Fixed Air in which he described a process of dripping sulfuric acid (or oil of vitriol as Priestley knew it) on chalk in order to produce carbon dioxide, and forcing the gas to dissolve by agitating a bowl of water in contact with the gas. Carbon dioxide was first liquefied (at elevated pressures) in 1823 by Humphry Davy and Michael Faraday.
The ability of a drug or other substance to be absorbed and used by the body. Orally bioavailable means that a drug or other substance that is taken by mouth can be absorbed and used by the body. (NCI) Bioinformatics
Sources: en.wikipedia.org
They are often used in kumbilappam or chakka-ada (ചക്ക അട), an authentic sweet from Kerala, infusing their characteristic flavor to the dumplings. When sold, they are often labeled as "Indian bay leaves", or just "bay leaf" , causing confusion with the leaf from the bay laurel, a tree of Mediterranean origin in a different genus; the appearance and aroma of the two are quite different. Bay laurel leaves are shorter and light- to medium-green in color, with one large vein down the length of the leaf, while tejpat leaves are about twice as long and wider, usually olive green in color, with three veins down the length of the leaf. There are five types of tejpat leaves and they impart a strong cassia- or cinnamon-like aroma to dishes, while the bay laurel leaf's aroma is more reminiscent of pine and lemon.
These peptides result from partial proteolysis of intracellular or extracellular protein precursors performed by several processing enzymes or protease complexes (rennin, kallikreins, calpains, prohormone convertases, proteasomes, endosomes, lysosomes), which convert proteins into peptides, including those with biological activities. The resulting protein fragments of various sizes are either readily degraded into free amino acids, or captured by oligopeptidases, whose peculiar binding and/or catalytic properties allow them to fulfill their physiological roles by trimming inactive peptide precursors leading to their active form, converting bioactive peptides into novel ones., inactivating them, thus restraining the continuous activation of specific receptors, or protecting the newly generated bioactive peptide from further degradation, suggesting a peptide chaperon-like activity. TOP, a ubiquitous cytosolic oligopeptidase, is a remarkable example of how this enzyme could play an essential role in immune defense against cancer cells. It has also been successfully used as a hook to fish novel bioactive peptides from cytosol of cells. The involvement of peptides in cell-cell interactions and in neuropsychiatric, autoimmune, and neurovegetative diseases are waiting for peptidomics and gene silencing approaches, which will expedite the formation of new concepts in an emerging era for oligopeptidases. The participation of oligopeptidases in a number of pathologies has long been reported.
Although the modern periodic table is standard today, the placement of the period 1 elements hydrogen and helium remains an open issue under discussion, and some variation can be found. Following their respective s1 and s2 electron configurations, hydrogen would be placed in group 1, and helium would be placed in group 2. The group 1 placement of hydrogen is common, but helium is almost always placed in group 18 with the other noble gases. The debate has to do with conflicting understandings of the extent to which chemical or electronic properties should decide periodic table placement. Like the group 1 metals, hydrogen has one electron in its outermost shell and typically loses its only electron in chemical reactions. Hydrogen has some metal-like chemical properties, being able to displace some metals from their salts. But it forms a diatomic nonmetallic gas at standard conditions, unlike the alkali metals which are reactive solid metals. This and hydrogen's formation of hydrides, in which it gains an electron, brings it close to the properties of the halogens which do the same (though it is rarer for hydrogen to form H− than H+). Moreover, the lightest two halogens (fluorine and chlorine) are gaseous like hydrogen at standard conditions. Some properties of hydrogen are not a good fit for either group: hydrogen is neither highly oxidizing nor highly reducing and is not reactive with water. Hydrogen thus has properties corresponding to both those of the alkali metals and the halogens, but matches neither group perfectly, and is thus difficult to place by its chemistry.
Sources: en.wikipedia.org
=== Chemical symbol === Deuterium is often represented by the chemical symbol D. Since it is an isotope of hydrogen with mass number 2, it is also represented by 2H. IUPAC allows both D and 2H, though 2H is preferred. A distinct chemical symbol is used for convenience because of the isotope's common use in various scientific processes. Also, its large mass difference with protium (1H) confers non-negligible chemical differences with 1H compounds. Deuterium has a mass of 2.014102 Da, about twice the mean hydrogen atomic weight of 1.007947 Da, or twice protium's mass of 1.007825 Da. The isotope weight ratios within other elements are largely insignificant in this regard.
Despite high total bismuth concentrations in the colon, antimicrobial activity in the colon is negligible because dominant forms of bismuth recovered (insoluble bismuth sulfide and methylated derivatives like TMBi) are microbiologically inactive; transformation into bismuth sulfide not only curtails further absorption but also minimizes potential toxicity and flora disruption.
Denmark has changed its energy consumption from 99% fossil fuels (92% oil (all imported) and 7% coal) and 1% biofuels in 1972 to 73% fossil fuels (37% oil (all domestic), 18% coal, 18% natural gas (all domestic)), and 27% renewables (largely biofuels) in 2015. The goal is a full independence of fossil fuels by 2050. This drastic change was initially inspired largely by the discovery of Danish oil and gas reserves in the North Sea in 1972 and the 1973 oil crisis. The course took a giant leap forward in 1984, when the Danish North Sea oil and gas fields, developed by native industry in close cooperation with the state, started major production. In 1997, Denmark became self-sufficient with energy, and the overall CO2 emission from the energy sector began to fall by 1996. Wind energy contribution to the total energy consumption has risen from 1% in 1997 to 5% in 2015. Since 2000, Denmark has increased gross domestic product (GDP) and at the same time decreased energy consumption. Since 1972, the overall energy consumption has dropped by 6%, even though the GDP has doubled in the same period. Denmark had the 6th best energy security in the world in 2014. Denmark has had relatively high energy taxation to encourage careful use of energy since the oil crises in the 1970s, and Danish industry has adapted to this and gained a competitive edge. The so-called "green taxes" have been broadly criticised partly for being higher than in other countries, but also for being more of a tool for gathering government revenue than a method of promoting "greener" behaviour.
Allergic reaction: There have been several studies conducted that show a precedence for allergenicity of silver nanoparticles. Argyria and staining: Ingested silver or silver compounds, including colloidal silver, can cause a condition called argyria, a discoloration of the skin and organs.In 2006, there was a case study of a 17-year-old man, who sustained burns to 30% of his body, and experienced a temporary bluish-grey hue after several days of treatment with Acticoat, a brand of wound dressing containing silver nanoparticles. Argyria is the deposition of silver in deep tissues, a condition that cannot happen on a temporary basis, raising the question of whether the cause of the man's discoloration was argyria or even a result of the silver treatment. Silver dressings are known to cause a "transient discoloration" that dissipates in 2–14 days, but not a permanent discoloration. Silzone heart valve: St. Jude Medical released a mechanical heart valve with a silver coated sewing cuff (coated using ion beam-assisted deposition) in 1997. The valve was designed to reduce the instances of endocarditis. The valve was approved for sale in Canada, Europe, the United States, and most other markets around the world. In a post-commercialization study, researchers showed that the valve prevented tissue ingrowth, created paravalvular leakage, valve loosening, and in the worst cases explantation. After 3 years on the market and 36,000 implants, St. Jude discontinued and voluntarily recalled the valve.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.